Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug.

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with ...

Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult ...

When Katelynn O’Connell takes her lunch break at work, she follows a routine that sets her apart from other employees. Each day at noon, she unfolds a cot in her small office, turns on a white noise ...

Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...

What Is Wakix, and Why Does It Matter? Wakix (pitolisant) is a prescription medication used to treat narcolepsy, a long-term neurological sleep disorder that causes excessive daytime sleepiness and, ...

Avadel Pharmaceuticals plc has published six manuscripts in a CNS Drugs supplement titled "A New Dawn in the Management of Narcolepsy," focusing on clinical management strategies, shared ...

SAN DIEGO -- AXS-12 (reboxetine), an investigational treatment for narcolepsy, reduced weekly cataplexy attacks and in some cases provided complete remission, the phase III SYMPHONY study showed. From ...

The "United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis" report has been added to ResearchAndMarkets.com's offering ...

Aug 27 (Reuters) - Drug companies Jazz (JAZZ.O), opens new tab and Hikma (HIK.L), opens new tab must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy drug ...

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...